Navigation Links
DuPont Reports First Quarter Earnings Growth of Over 20 Percent
Date:4/22/2008

Sales Increase 9 Percent with Strong Growth in Agriculture and Emerging

Markets
WILMINGTON, Del., April 22 /PRNewswire-FirstCall/ --

Highlights

-- First quarter 2008 earnings were $1.31 per share compared to $1.01 in

the prior year. Excluding a significant item charge in the prior year,

earnings per share increased 22 percent.

-- Sales grew 9 percent to $8.6 billion, reflecting 6 percent higher local

selling prices and 5 percent currency benefit, partly offset by

1 percent lower volume and a net 1 percent reduction principally due to

a chemical business divestiture. Local selling price gains more than

offset higher ingredient costs.

-- Sales in Agriculture & Nutrition increased 18 percent and earnings grew

21 percent, reflecting strong demand for the company's production

agriculture products.

-- Sales in emerging markets grew 25 percent, led by Brazil, China, India

and Eastern Europe.

-- Reduced demand in the United States for the company's products sold

into construction and motor vehicle markets moderated results in the

Safety & Protection and Coatings & Color Technologies segments.

-- Segment pre-tax operating income (PTOI) increased to $1.9 billion.

Excluding significant items, segment PTOI margin improved 1 percentage

point to 21 percent.

"We're off to a strong start for the year," said DuPont Chairman and CEO Charles O. Holliday, Jr. "Our investments in agriculture and emerging markets enabled us to capitalize on robust growth in those areas which, when combined with gains from our productivity improvement programs, more than offset higher ingredient costs and weakness in certain U.S. markets. We'll continue to drive faster revenue growth from science-based, high value-added products and greater productivity."

"Despite the impact of w
'/>"/>

SOURCE DuPont
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. DuPont Leaders Brief Investors on Agriculture Businesses
2. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
3. DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration
4. DuPont Named Among Top Biotechnology Employers by Science Magazine
5. Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize
6. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
7. DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest
8. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
9. DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum
10. DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development
11. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...wswire/--CromozInc.,locatedinResearchTrianglePark,...rdrugdeliverysysteminHyderabad,India.Thewater-solu...allsthatallowsforconjugationwithcancerdrugs,wasdev...ITT).Theconjugatedcarbonnanotubesservesasadrugdeli...hhasthepotentialtoincreasethedrugefficacy. ,, T...
(Date:11/27/2009)...wire-FirstCall/--Stallergeneshasbeen,grantedEurope...n,throughaMutualRecognitionProcedure.Germany,thefi...ferenceMemberstate. , Oralair(R)isnowregister...lic,Estonia,France,Germany,Greece,Hungary,Ireland,...lands,Poland,Portugal,Romania,Slovakia,Slovenia,a...
(Date:11/27/2009)...hanised blue dye test alternative is helping bri...nce one step closer for pharma-companies. It is a ...e developed by Sepha for use with blister packs ... and global pharma-companies such as Sanofi-Avenis...d productivity improvements on the packaging line....
(Date:11/26/2009)...new generation of ultrasmall transistors and more ...ed semiconducting nanowires are closer to reality ...e University and the University of California at L...o create nanowires with layers of different materi...which is a critical requirement for making efficie...
Breaking Biology Technology:North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) will re... and fiscal year ending December 31, 2008 on Thurs....S. financial markets. The Company will also host...11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) t...nt will provide a business update and will discuss...
... Sigma-Aldrich (Nasdaq: SIAL ),today announced ...PC,Scientific, a leading provider of high quality ... APIs for the pharmaceutical and biotechnology ind...tific will offer Sigma-Aldrich,s,PEPscreen(R) cust...een ) to life,science researchers and pharmaceutic...
...9 Amicus Therapeutics (Nasdaq: FOLD ) will anno...esults after the regular close of markets on Thurs...ll be followed by a live conference call and webca...participants and investors may access the conferen..../Canada) or 719-325-4870 (international). A telep...
Other Biology Technology:SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries 2Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries 3Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:11/26/2009)...n,s most distinctive residents. ,Everyone wants to..., says Michelle McComb from Florida Atlantic Unive...,Perhaps their visual field has been enhanced by t...arks excellent stereovision and depth perception. ...ls of thought on this theory. In 1942, G. Walls sp...
(Date:11/26/2009)...ed deer have been caught in the hunters, sights fo...than decorative. They are lethal weapons that stag...The University of York, UK, has been intrigued by ...century and has become fascinated by the mechanica...laboration with Tomas Landete-Castillejos at the U...
(Date:11/26/2009)...ay of using recordings of birdsong to accurately m...irst time sound recordings from a microphone array...ird species, populations. Because the new techniqu...ournal of Applied Ecology , will also work with wh...ability to monitor whale and dolphin numbers. , ...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Tough yet stiff deer antler is materials scientist's dream 2Ecologists sound out new solution for monitoring cryptic species 2Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 1Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 2Florida 26apos 3Bs Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10 Story Emergency Facility 59788 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 1Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 2Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 3Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 4Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 5Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 6Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 7Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 8Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 9Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 10Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 11Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 12Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 13Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 14Novartis drug Tasigna 28R 29 meets primary endpoint in pivotal trial against Gleevec 28R 29 as first line treatment in chronic myeloid leukemia patien 5579 15LIVESTRONG 28R 29 Receives 24211 306 Donation from Eagle Golf 59782 1LIVESTRONG 28R 29 Receives 24211 306 Donation from Eagle Golf 59782 2
... of the worlds leading STM publishers, has signed ...ntific societies during the past half year. With ...resentative selection of Korean society journals a...blishing the increasing amount of research coming ... journals in 2008 were signed with the Korean Soci...
...rents need to be educated about managing fever in ...ectly and often unnecessarily, according to a Quee.... , QUT senior research fellow Anne Walsh conduct...nage childhood fever as part of her PhD. , Her re...iatrics and Child Health. , Ms Walsh found that, ...
...TE, Ind. - Researchers have developed a breed of A...light that decimated its population in the early 1...o-called for its picturesque form and towering hei...lew of obstacles, said a Purdue University researc...t blight, but there is a whole new set of obstacle...
Other Biology News:Fever causing headaches for Aussie parents 2Challenges remain in reintroducing American chestnut 2Challenges remain in reintroducing American chestnut 3
... expression profiling and built on the flexible an...platform. These microarrays are available as part ... Service. Probe Content The Fishes microRNA Mic...que mature sequences). The comprehensive probe con...
... expression profiling and built on the flexible an...platform. These microarrays are available as part ... Service. Probe Content The Maize microRNA Micr...ue mature sequences). The comprehensive probe cont...
...itative and qualitative capabilities of the 4000 Q...w Tempo nano MDLC System plus automation software,...validation of protein biomarkers. , , Eliminate e...electivity and sensitivity. , Build methods quick...
...nce of the LTQ, incorporating more techniques to g...ntifics innovations in ion trap technology. Therm...r that offers multiple dissociation techniques, PQ...iation (PQD) is a patented technique that eliminat...
Biology Products: